Analysts Offer Predictions for Immunocore FY2024 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Research analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for Immunocore in a report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($1.48) per share for the year, up from their prior estimate of ($2.20). The consensus estimate for Immunocore’s current full-year earnings is ($1.71) per share. Leerink Partnrs also issued estimates for Immunocore’s Q4 2024 earnings at ($0.93) EPS and FY2025 earnings at ($2.59) EPS.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The company had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. During the same period in the previous year, the company posted ($0.59) earnings per share. Immunocore’s revenue for the quarter was up 23.7% on a year-over-year basis.

IMCR has been the subject of several other reports. Needham & Company LLC reduced their target price on Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a research note on Thursday. Guggenheim downgraded Immunocore from a “buy” rating to a “neutral” rating in a research note on Monday, October 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Thursday, October 24th. Finally, UBS Group initiated coverage on Immunocore in a research note on Thursday, October 24th. They set a “sell” rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and an average target price of $73.73.

Immunocore Trading Up 2.4 %

Shares of NASDAQ:IMCR opened at $34.31 on Friday. The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $1.72 billion, a PE ratio of -32.14 and a beta of 0.72. The business has a 50 day moving average of $32.67 and a two-hundred day moving average of $39.70. Immunocore has a 12-month low of $29.72 and a 12-month high of $76.98.

Institutional Investors Weigh In On Immunocore

Hedge funds and other institutional investors have recently made changes to their positions in the business. Exchange Traded Concepts LLC increased its position in Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after buying an additional 1,461 shares during the period. Tidal Investments LLC acquired a new position in Immunocore during the first quarter worth $423,000. Nan Fung Group Holdings Ltd acquired a new position in Immunocore during the first quarter worth $439,000. Connective Portfolio Management LLC acquired a new position in Immunocore during the third quarter worth $218,000. Finally, DNB Asset Management AS raised its holdings in Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.